Skip to contentA
Alnylam Pharmaceuticals, Inc.
A
ALNYAlnylam Pharmaceuticals, Inc. Q1 2019 · 10-Q
Revenue$33.29M$33.29M+52.0% vs Q1 2018 Net Income-$181.92M-$181.92MN/M vs Q1 2018 EPS Diluted-$1.73-$1.73N/M vs Q1 2018 Operating Income-$188,788,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
Free Cash Flowderived-$232,559,000N/M Margins · derivedOperating margin-567.0%+106.1 pt vs Q1 2018
Net margin-546.4%+98.5 pt vs Q1 2018
ended Mar 31, 2019 · filed May 2, 2019 · 32 d after period end